



## Genoskin Strengthens Its Governance with the Appointment of Fabrice Bouteille as an Independent Board Member

Toulouse, France and Salem, MA – April 2026 – Genoskin, a Contract Research Organization (CRO) and supplier of human skin models and primary mast cells, is transforming drug, medical device, cosmetics, and personal product development through its unique expertise in skin biology and immunology and its ability to generate human-relevant immunological data. Today, the company announced the appointment of Fabrice Bouteille as an independent member of its Board of Directors.

This appointment marks a new step in Genoskin's post-Series A trajectory, following the company's \$8.7 million (€8 million) financing completed in September 2025 to accelerate international expansion, scale operations, and reinforce its scientific leadership. As part of this next phase, Genoskin is further strengthening its governance structure to support sustained growth and future strategic milestones.

The onboarding of an independent Board member reflects Genoskin's commitment to building best-in-class governance aligned with international standards. It also signals the company's continued focus on independence, transparency, and high-quality decision-making as it expands its footprint across the United States and Europe and broadens its impact across pharmaceuticals, biotechnology, and medical devices—an increasingly strategic growth area for the company.

Fabrice Bouteille brings more than 20 years of global leadership experience across the healthcare, drug delivery, and MedTech sectors. His expertise spans injectable drug delivery devices, primary packaging, and pharmaceutical systems, with deep knowledge of both oral and parenteral drug formats.

Over the course of his career, Fabrice has held senior commercial and business development roles across multiple geographies, working with organizations ranging from high-growth SMEs to global leaders such as Pfizer, KKR, and Aptar. As Vice President Global Sales for Aptar Pharma Injectables and member of the Global Leadership Team, he led international growth initiatives across North America, EMEA, and Asia.

In 2022, Fabrice founded his own consulting firm supporting B2B healthcare companies in optimizing strategy, enhancing commercial performance, and accelerating international expansion.

In a highly differentiated approach, Genoskin partnered with APIA (Administrateurs Professionnels Indépendants Associés), a non-profit organization dedicated to promoting high-quality governance in SMEs and mid-sized companies, to identify and recruit its independent Board members.

---

GENOSKIN SAS  
+33 972 476 029  
1, Place Pierre Potier  
31100 Toulouse, France  
TVA FR00535121933

GENOSKIN INC  
+1 (617) 416 5358  
4 Technology way  
Salem, MA 01970, USA

marketing@genoskin.com  
genoskin.com



APIA brings together experienced executives and CEOs who serve as independent directors and ensures a rigorous selection process based on experience, independence, and ethics. By leveraging this structured, third-party, mission-driven organization, Genoskin has reinforced the objectivity and integrity of its Board composition—going beyond traditional reliance on investor or personal networks.

“Fabrice’s appointment is a natural continuation of our Series A and a key step in building a governance framework that matches our global ambitions,” said **Pascal Descargues**, CEO and Founder of Genoskin. “His experience and independent perspective will be invaluable as we continue scaling our operations and expanding into key growth areas, including medical devices.”

“I am honored to join Genoskin’s Board and to support its mission of advancing human-relevant solutions in drug development,” said **Fabrice Bouteille**. “Genoskin’s unique technology and dedicated team are already driving cross-continental impact for pharmaceutical and biotech partners. I look forward to contributing to the company’s strategic growth and helping innovators advance safer, more effective therapies.”

With this appointment, Genoskin continues to position itself as a trusted partner for life sciences companies, advancing innovative and ethical approaches to drug and medical device development.

### **About Genoskin**

*Genoskin is a Contract Research Organization (CRO) and supplier of human skin models and primary mast cells, transforming drug development through its unique expertise in skin biology and immunology. By leveraging donated human skin and proprietary preservation technologies, Genoskin provides immunocompetent ex vivo platforms that enable more translational, human-relevant testing than traditional animal or engineered models, and align with the evolving regulatory expectations outlined in the FDA Modernization Act 2.0.*

*Founded in 2011, Genoskin offers a suite of advanced solutions to evaluate immune responses, injection site reactions and skin toxicity across therapeutics, biologics, vaccines, medical devices and chemicals. Through a combination of next-generation sequencing, advanced imaging and expert scientific guidance, Genoskin supports pharmaceutical, biotechnology and cosmetics companies in generating robust, translational human data to accelerate development with greater confidence.*

*In September 2025, Genoskin successfully completed an €8 million (\$8.7M) fundraising round led by OCCTE (FPCI Occidev Impacts), alongside Captech Santé, GSO Innovation and CA Toulouse 31 Initiatives, with additional non-dilutive financing from Bpifrance and leading banking partners. This financing supports Genoskin’s next phase of growth, including doubling its workforce over the next three years, expanding its commercial presence in key global markets - particularly in Europe and Asia - and scaling operations through facility expansion in the US and France.*

---

GENOSKIN SAS  
+33 972 476 029  
1, Place Pierre Potier  
31100 Toulouse, France  
TVA FR00535121933

GENOSKIN INC  
+1 (617) 416 5358  
4 Technology way  
Salem, MA 01970, USA

marketing@genoskin.com  
genoskin.com



*As part of its growth strategy, Genoskin is advancing new immune-centric service offerings, accelerating the development of biosimulation platforms and next-generation human immune models, and increasing production capacity to meet the rising demand for ethical, human-relevant alternatives to animal testing.*

*Headquartered in North America and Europe, Genoskin operates state-of-the-art R&D and production facilities in Salem, Massachusetts (USA) and Toulouse, France, with about 50 employees across France and the United States.*  
[www.genoskin.com](http://www.genoskin.com)

### **About APIA**

*APIA (Administrateurs Professionnels Indépendants Associés) is a French association that brings together experienced independent board members committed to promoting high standards of corporate governance. @APIA supports the professionalization of board roles, fosters best practices, and contributes to the development of strategic oversight within companies, particularly mid-sized organizations.*

---

GENOSKIN SAS  
+33 972 476 029  
1, Place Pierre Potier  
31100 Toulouse, France  
TVA FR00535121933

GENOSKIN INC  
+1 (617) 416 5358  
4 Technology way  
Salem, MA 01970, USA

marketing@genoskin.com  
genoskin.com